Role of single photon emission computed tomography imaging in the evaluation of therapy for angina pectoris

American Heart Journal

Volumn 145, Issue 6, 2003, Pages 952-961

  Patel, Amar D ^a   Iskandrian, Ami E ^a,b  

^a University of Alabama at Birmingham   (United States)

^b and Clinical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; ANTIANGINA PECTORIS AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPYRIDAMOLE; FIBROBLAST GROWTH FACTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOSORBIDE MONONITRATE; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; NICORANDIL; NITRATE; PRAVASTATIN; THALLIUM 201; VASCULOTROPIN; ENDOTHELIAL CELL GROWTH FACTOR; LYMPHOKINE; SIGNAL PEPTIDE; VASCULOTROPIN A;

ANGINA PECTORIS; ANGIOGENESIS; CLINICAL TRIAL; CORONARY ARTERY; DRUG EFFICACY; EVALUATION; HEART MUSCLE BLOOD FLOW; HEART MUSCLE REVASCULARIZATION; HUMAN; LOW LEVEL LASER THERAPY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DISEASE; DRUG EFFECT; EXERCISE TEST; LASER SURGERY; METHODOLOGY; PHYSIOLOGY; SCINTISCANNING;

ANGINA PECTORIS; CLINICAL TRIALS; CORONARY CIRCULATION; CORONARY DISEASE; ENDOTHELIAL GROWTH FACTORS; EXERCISE TEST; FIBROBLAST GROWTH FACTORS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LASER SURGERY; LYMPHOKINES; MYOCARDIAL REVASCULARIZATION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0038281527     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(03)00088-7     Document Type: Review

References (111)

1. Beller GA, Zaret BL. Contributions of nuclear cardiology to diagnosis and prognosis of patients with coronary artery disease. Circulation 2000;101:1465-78.
2. Gibbons RJ, Miller TD, Christian TF. Infarct size measured by single photon emission computed tomographic imaging with 99m-Tc-sestamibi. Circulation 2000;101:101-8.
3. Iskandrian AE, Verani MS, editors. Nuclear cardiac imaging: principles and applications. 2nd ed. Philadelphia: FA Davis; 1996.
4. Iskandrian AS, Verani MS, Heo J. Pharmacologic stress testing: mechanism of action, hemodynamic responses, and results in detection of coronary artery disease. J Nucl Cardiol 1994;1:94-111.
5. DePuey EG, Garcia EV. Optimal specificity of thallium-201 SPECT through recognition of imaging artifacts. J Nucl Med 1989;30:441-9.
6. Germano G, Chua T, Kavanagh PB, et al. Detection and correction of patient motion in dynamic and static myocardial SPECT using a multi-detector camera. J Nucl Med 1993;34:1349-55.
7. Narula J, Dawson MS, Singh BK, et al. Noninvasive characterization of stunned, hibernating, remodeled and nonviable myocardium in ischemic cardiomyopathy. J Am Coll Cardiol 2000;36:1913-9.
8. Sharir T, Germano G, Waechter PB, et al. A new algorithm for the quantitation of myocardial perfusion SPECT. II: validation and diagnostic yield. J Nucl Med 2000;41:720-7.
9. Mahmarian JJ, Moye LA, Verani MS, et al. High reproducibility of myocardial perfusion defects in patients undergoing serial exercise thallium-201 tomography. Am J Cardiol 1995;75:1116-9.
10. Alazraki NP, Krawczynska EG, DePuey EG, et al. Reproducibility of thallium-201 exercise SPECT studies. J Nucl Med 1994;35:1237-44.
11. Prigent FM, Berman DS, Elashoff J, et al. Reproducibility of stress redistribution thallium-201 SPECT quantitative indexes of hypoperfused myocardium secondary to coronary artery disease. Am J Cardiol 1992;70:1255-63.
12. Burkhoff D, Jones JW, Becket LC, et al. Variability of myocardial perfusion defects assessed by thallium-201 scintigraphy in patients with coronary artery disease not amenable to angioplasty or bypass surgery. J Am Coll Cardiol 2001;38:1033-9.
13. Burkhoff D, Schmidt S, Schulman SP, et al. Transmyocardial laser revascularisation compared with continued medical therapy for treatment of angina pectoris: a prospective randomised trial. Lancet 1999;354:885-90.
14. Whittaker P, Kloner RA. Transmural channels as a source of blood flow to ischemic myocardium? Circulation 1997;95:1357-9.
15. Kohmoto T, Argenziano M, Yamamoto N, et al. Assessment of transmyocardial perfusion in alligator hearts. Circulation 1997;95:1585-91.
16. Mirhoseini M, Cayton MM. Revascularization of the heart by laser. J Microsurg 1981;2:253-60.
17. Yamamoto N, Kohmoto T, Gu A, et al. Angiogenesis is enhanced in ischemic canine myocardium by transmyocardial laser revascularization. J Am Coll Cardiol 1998;31:426-33.
18. Sayeed-Shah U, Mann M J, Martin J, et al. Complete reversal of ischemic wall motion abnormalities by combined use of gene therapy with transmyocardial laser revascularization. J Thorac Cardiovasc Surg 1998;116:763-9.
19. Horvath KA, Smith WJ, Laurence RG, et al. Recovery and viability of an acute myocardial infarct after transmyocardial laser revascularization. J Am Coll Cardiol 1995;25:258-63.
20. Diegeler A, Schneider J, Lauer B, et al. Transmyocardial laser revascularization using the Holium-YAG laser for treatment of end stage coronary artery disease. Eur J Cardiothorac Surg 1998;13:392-7.
21. Lauer B, Junghans U, Stahl F, et al. Catheter-based percutaneous myocardial laser revascularization in patients with end-stage coronary artery disease. J Am Coll Cardiol 1999;34:1663-70.
22. Kavanagh GJ, Whittaker P, Prejean CA, et al. Dissociation between improvement in angina pectoris and myocardial perfusion after transmyocardial revascularization with an excimer laser. Am J Cardiol 2001;87:229-31.
23. Schneider J, Diegeler A, Krakor R, et al. Transmyocardial laser revascularization with the holium: YAGlaser: loss of symptomatic improvement after 2 years. Eur J Cardiothorac Surg 2001;19:164-9.
24. Horvath KA, Cohn LH, Cooley DA, et al. Transmyocardial laser revascularization; results of a multicenter trial with transmyocardial laser revascularization used as a sole therapy for end-stage coronary artery disease. J Thorac Cardiovasc Surg 1997;113:645-54.
25. Milano A, Pratlai S, Tartarini G, et al. Early results of transmyocardial revascularization with a holium laser. Ann Thorac Surg 1998;65:700-4.
26. Allen KB, Dowling RD, Fudge TL, et al. Comparison of transmyocardial revascularization with medical therapy in patients with refractory angina. N Engl J Med 1999;341:1029-36.
27. Frazier OH, March RJ, Horvath KA, et al. Transmyocardial revascularization with a carbon dioxide laser in patients with end-stage coronary artery disease. N Engl J Med 1999;341:1021-8.
28. Schofield PM, Sharples LD, Caine N, et al. Transmyocardial revascularisation in patients with refractory angina: a randomised controlled trial. Lancet 1999;353:519-24.
29. Horvath KA, Mannting P, Cummings N, et al. Transmyocardial laser revascularization: operative techniques and clinical results at two years. J Thorac Cardiovasc Surg 1996;111:1047-53.
30. Cooley DA, Frazier OH, Kadipasaoglu KA, et al. Transmyocardial laser revascularization: clinical experience with twelve-month follow-up. J Thorac Cardiovasc Surg 1996;111:791-9.
31. Frazier OH, Cooley DA, Kadipasaoglu KA, et al. Myocardial revascularization with laser. Circulation 1995;92(Suppl 2):II-58-65.
32. Nagele H, Stubbe HM, Nienaber C, et al. Results of transmyocardial laser revascularization in non-revascularizable coronary artery disease after 3 years follow-up. Eur Heart J 1998;19:1525-30.
33. Vincent JG, Bardos P, Kruse J, Maass D. End stage coronary disease treated with the transmyocardial CO2 laser revascularisation: a chance for the "inoperable" patient. Eur J Cardiothorac Surg 1997;11:888-94.
34. Agarwal A, Ajit M, Kurian VM, et al. Transmyocardial laser revascularization: early results and 1-year follow-up. Ann Thorac Surg 1999;67:432-6.
35. Lee LY, O'Hara MF, Finnin EB, et al. Transmyocardial laser revascularization with excimer laser: clinical results at 1 year. Ann Thorac Surg 2000;70:498-503.
36. Stoll HP, Hutchins GD, Fain RL, et al. Transmyocardial laser revascularization (TMR) induces regional myocardial denervation (abstract). Circulation 1998;98(Suppl 1):349.
37. Kohomoto T, Fisher PE, Gu A, et al. Physiology, histology, and 2 week morphology of acute transmyocardial channels made with a CO2 laser. Ann Thorac Surg 1997;63:1275-83.
38. Krabatsch T, Schaper F, Leder C, et al. Histological findings after transmyocardial laser revascularization. J Card Surg 1996;11:326-31.
39. Hardy RI, Bove KE, James FW, et al. A histologic study of laser-induced transmyocardial channels. Lasers Surg Med 1987;6:563-73.
40. Gassier N, Wintzer HO, Stubbe HM, et al. Transmyocardial laser revascularization: histological features in human nonresponder myocardium. Circulation 1997;95:371-5.
41. Schaper W, Ito WD. Molecular mechanisms of coronary collateral vessel growth. Circ Res 1996;79:911-9.
42. Flier JS, Underhill LH. Clinical applications of research on angiogenesis. N Engl J Med 1995;333:1757-63.
43. Isner JM, Asahara T. Angiogenesis and vasculogenesis as therapeutic stategies for postnatal neovascularization. J Clin Invest 1999;103:1231-6.
44. Lee SH, Wolf PL, Escudero R, et al. Early expression of angiogenesis factors in acute myocardial infarction. N Engl J Med 2000;342:626-33.
45. Ware JA, Simons M. Angiogenesis in ischemic heart disease. Nat Med 1997;3:158-64.
46. Takeshita S, Zheng LP, Brogi E, et al. Therapeutic angiogenesis. J Clin Invest 1994;93:662-70.
47. Grines CL, Watkins MW, Helmer G, et al. Angiogenic gene therapy (AGENT) trial in patients with stable angina pectoris. Circulation 2002;105:1291-7.
48. Losordo DW, Vale PR, Hendel RC, et al. Phase 1/2 placebo-controlled, double-blind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia. Circulation 2002;105:2012-8.
49. Baumgartner I, Pieczek A, Manor O, et al. Constitutive expression of ph VEGF-165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation 1998;97:1114-23.
50. Tsurumi Y, Takeshita S, Chen D, et al. Direct intramuscular gene transfer of naked DNA encoding vascular endothelial growth factor augments collateral development and tissue perfusion. Circulation 1996;94:3281-90.
51. Giordano FJ, Ping P, McKirnan MD, et al. Intracoronary gene transfer of fibroblast growth factor-5 increases blood flow and contractile function in an ischemic region of the heart. Nat Med 1996;2:534-9.
52. Harada K, Grossman W, Friedman M, et al. Basic fibroblast growth factor improves myocardial function in chronically ischemic porcine hearts. J Clin Invest 1994;94:623-30.
53. Battler A, Scheinowitz M, Bor A, et al. Intracoronary injection of basic fibroblast growth factor enhances angiogenesis in infarcted swine myocardium. J Am Coll Cardiol 1993;22:2001-6.
54. Banal S, Jaklitsch MT, Shou M, et al. Angiogenic-induced enhancement of collateral blood flow to ischemlc myocardium by vascular endothelial growth factor in dogs. Circulation 1994;89:2183-9.
55. Harada K, Freidman M, Lopez JJ, et al. Vascular endothelial growth factor administration in chronic myocardial ischemia. Am J Physiol 1996;270:H1791-802.
56. Unger EF, Banai S, Shou M, et al. Basic fibroblast growth factor enhances myocardial collateral flow in a canine model. Am J Physiol 1994;266:H1588-95.
57. Lopez JJ, Edelman ER, Stamler A, et al. Basic fibroblast growth factor in a porcine model of chronic myocardial ischemia: a comparison of angiographic, echocardiographic and coronary flow parameters. J Pharmacol Exp Ther 1997;282:385-90.
58. Miwa-Yanagisawa A, Uchida Y, Nakamura F, et al. Salvage of infarcted myocardium by angiogenic action of basic fibroblast growth factor. Science 1992;257:1401-3.
59. Sellke FW, Li J, Stamler A, et al. Angiogenesis induced by acidic fibroblast growth factor as an alternative method of revascularization for chronic myocardial ischemia. Surgery 1996;120:182-8.
60. Symes JF, Losordo DW, Vale PR, et al. Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease. Ann Thorac Surg 1999;68:830-7.
61. Hendel RC, Henry TD, Rocha-Singh K, et al. Effect of intracoronary recombinant human vascular endothelial growth factor on myocardial perfusion. Circulation 2000;101:118-21.
62. Udelson JE, Dilsizian V, Laham RJ, et al. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 improves stress and rest myocardial perfusion abnormalities in patients with severe symptomatic chronic coronary artery disease. Circulation 2000;102:1605-10.
63. Vale PR, Losordo DW, Milliken CE, et al. Left ventricuiar electromechanical mapping to assess efficacy of phVEGF-165 gene transfer for therapeutic angiogenesis in chronic myocardial ischemia. Circulation 2000;102:965-74.
64. Vale PR, Losordo DW, Milliken CE, et al. Randomized, single-blind, placebo-controlled pilot study of catheter-based myocardial gene transfer for therapeutic angiogenesis using left ventricular electromechanical mapping in patients with chronic myocardial ischemia. Circulation 2001;103:2138-43.
65. Losordo DW, Vale PR, Symes JF, et al. Gene therapy for myocardial angiogenesis. Initial clinical results with direct myocardial injection of phVEGF-165 as sole therapy for myocardial ischemia. Circulation 1998;98:2800-4.
66. Rosengart TK, Lee LY, Patel SR, et al. Phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation 1999;100:468-74.
67. Sellke FW, Laham RJ, Edelman ER, et al. Therapeutic angiogenesis with basic fibroblast growth factor: technique and early results. Ann Thorac Surg 1998;65:1540-4.
68. Laham RJ, Sellke FW, Edelman ER, et al. Local perivascular delivery of basic fibroblast growth factor in patients undergoing coronary bypass surgery. Circulation 1999;100:1865-71.
69. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study. Lancet 1994;344:1383-9.
70. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-9.
71. Pitt B, Mancini GBJ, Ellis SG, et al. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. J Am Coll Cardiol 1995;26:1133-9.
72. Waters D, Higginson L, Gladstone P, et al. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. Circulation 1994;89:959-68.
73. Jukema JW, Brushke AVG, van Boven AJ, et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. Circulation 1995;91:2528-40.
74. Blankenhorn DH, Azen SP, Kramsch DM, et al. Coronary angiographic changes with lovastatin therapy. Ann Intern Med 1993;119:969-76.
75. Leung WH, Lau CP, Wong CK. Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolemic patients. Lancet 1993;341:1496-500.
76. Treasure CB, Klein JL, Weintraub WS, et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995;332:481-7.
77. O'Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 1997;95:1126-31.
78. Egashira K, Hirooka Y, Kai H, et al. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomation in patients with hypercholesterolemia. Circulation 1994;89:2519-24.
79. Rim SJ, Leong-Poi H, Linder JR, et al. Decrease in coronary blood flaw reserve during hyperlipidemia is secondary to an increase in blood viscosity. Circulation 2001;104:2704-9.
80. Eichstadt HW, Abletshauser CB, Stork T, et al. Beneficial effects of fluvastatin on myocardial blood flow at two time-points in hypercholesterolemic patients with coronary artery disease. J Cardiovasc Pharmacol 2000;35:735-40.
81. Mostaza JM, Gomez MV, Gallardo F, et al. Cholesterol reduction improves myocardial perfusion abnormalities in patients with coronary artery disease and average cholesterol levels. J Am Coll Cardiol 2000;35:76-82.
82. Gould KL, Martucci JP, Goldberg DI, et al. Short-term cholesterol lowering decreases size and severity of perfusion abnormalities by positron emission tomography after dipyridamole in patients with coronary artery disease. Circulation 1994;89:1530-8.
83. Schwartz RG, Pearson TA. Can single photon emission computed tomography myocardial perfusion imaging monitor the potential benefit of aggressive treatment of hyperlipidemia? J Nucl Cardiol 1997;4:555-68.
84. Yokoyama I, Yonekura K, Inoue Y, et al. Long-term effect of simvastatin on the improvement of impaired myocardial flow reserve in patients with familial hypercholesterolemia without gender variance. J Nucl Cardiol 2001;8:445-51.
85. Chaitman BR, Stone PH, Knatterud GL, et al. Asymptomatic cardiac ischemia pilot (ACIP) study: impact of anti-ischemia therapy on 12-week rest electrocardiogram and exercise test outcomes. J Am Coll Cardiol 1995;26:585-93.
86. Pepine CJ, Lopez LM, Bell DM, et al. Effects of intermittent transdermal nitroglycerin on occurrence of ischemia after patch removal: results of the second transdermal intermittent dosing evaluation study (TIDES-II). J Am Coll Cardiol 1997;30:955-61.
87. Meluzin J, Zeman K, Stetka F, et al. Effects of nifedipine and diltiazem on myocardial ischemia in patients with severe stable angina pectoris treated with nitrates and beta-blockers. J Cardiovasc Pharmacol 1992;20:864-9.
88. Messin R, Karpov Y, Baikova N, et al. Short- and long-term effects of molisidomine retard and molsidomine nonretard on exercise capacity and clinical status in patients with stable angina: a multicenter randomized double-blind crossover placebo-controlled trial. J Cardiovasc Pharmacol 1998;31:271-6.
89. Rajaratnam R, Brieger DB, Hawkins R, et al. Attenuation of anti-ischemic efficacy during chronic therapy with nicorandil in patients with stable angina pectoris. Am J Cardiol 1999;83:1120-4.
90. Hamer AWF. Placebo effect of nitrate monotherapy for myocardial ischemia. Am J Cardiol 1992;70:1238-42.
91. Singh N, Mironov D, Goodman S, et al. Treatment of silent ischemia in unstable angina: a randomized comparison of sustained-release verapamil versus metoprolol. Clin Cardiol 1995;18:653-8.
92. DeMots H, Glasser SP. Intermittent transdermal nitroglycerin therapy in the treatment of chronic stable angina. J Am Coll Cardiol 1989;13:786-93.
93. Rossetti E, Luca C, Bonetti F, et al. Transdermal nitroglycerin reduces the frequency of anginal attacks but fails to prevent silent ischemia. J Am Coll Cardiol 1993;21:337-42.
94. Bridges AB, Kennedy N, McNeill GP, et al. The effect of atenolol on dipyridamole 201-Tl myocardial perfusion tomography in potients with coronary artery disease. Nucl Med Comm 1992;13:41-6.
95. Narahara K, Thompson CJ, Hazen JF, et al. The effect of beta blockade on single photon emission computed tomographic (SPECT) thallium-201 images in patients with coronary disease. Am Heart J 1989;117:1030-5.
96. Hockings B, Saltissi S, Croft DN, et al. Effect of beta adrenergic blockade on thallium-201 myocardial perfusion imaging. Br Heart J 1983;49:83-9.
97. Rainwater J, Steele P, Kirch D, et al. Effect of propanolol on myocardial perfusion images and exercise ejection fraction in men with coronary artery disease. Circulation 1982;65:77-81.
98. Marie PY, Danchin N, Branly F, et al. Effects of medical therapy on outcome assessment using exercise thallium-201 single photon emission computed tomography imaging. J Am Coll Cardiol 1999;34:113-21.
99. Billinger M, Seiler C, Fleisch M, et al. Do beta-adrenergic blocking agents increase coronary flow reserve? J Am Coll Cardiol 2001;38:1866-71.
100. Steele P, Sklar J, Kirch D, et al. Thallium-201 myocardial imaging during maximal and submaximal exercise: comparison of submaximal exercise with propanolol. Am Heart J 1983;106:1353-7.
101. Mahmarian JJ, Fenimore NL, Marks GF, et al. Transdermal nitroglycerin patch therapy reduces the extent of exercised-induced myocardial ischemia: results of a double-blind, placebo-controlled trial using quantitative thallium-201 tomography. J Am Coll Cardiol 1994;24:25-32.
102. Goller V, Clausen M, Henze E, et al. Reduction of exercise-induced myocardial perfusion defects by isosorbide-5-nitrate: assessment using quantitative Tc-99m-MIBI-SPECT. Coron Art Dis 1995;6:245-9.
103. Lewin HC, Hachamovitch R, Harris AG, et al. Sustained reduction of exercise perfusion defect extent and severity with isosorbide mononitrate (Imdur) as demonstrated by means of technetium 99m sestamibi. J Nucl Cardiol 2000;7:342-53.
104. Yamazaki J, Ohsawa H, Uchi T, et al. Study of the efficacy of nicorandil in patients with ischemic heart disease using exercise-Tl-201 myocardial tomography. Eur J Clin Pharmacol 1993;44:211-7.
105. Zervos G, Zusman RM, Swindle LA, et al. Effects of nifedipine on myocardial blood flow and systolic function in humans with ischemic heart disease. Coron Artery Dis 1999;10:185-94.
106. Zimmermann R, Tillmanns H, Kapp M, et al. Reduction of myocardial ischemia by gallopamil: a dual-isotope study with thallium-201 and iodine-123 phenylpentadecanoic acid. J Cardiovasc Pharmacol 1992;20(Suppl. 7):S40-7.
107. Rousseau MF, Melin J, Benedict CR, et al. Effects of nisoldipine therapy on myocardial perfusion and neuro-hormonal status in patients with severe ischemic left ventricular dysfunction. Eur Heart J 1994;15:957-64.
108. Dakik HA, Kleiman NS, Farmer JA, et al. Intensive medical therapy versus coronary angioplasty for suppression of myocardial ischemia in survivors of acute myocardial infarction. Circulation 1998;98:2017-23.
109. Sharir T, Rabinowitz B, Livschitz S, et al. Underestimation of extent and severity of coronary artery disease by dipyridamole stress thallium-201 single photon emission computed tomographic myocardial perfusion imaging in patients taking antionginal drugs. J Am Coll Cardiol 1998;31:1540-6.
110. Stegaru B, Loose R, Keler H, et al. Effects of long-term treatment with 120 mg of sustained-release isosorbide dinitrate and 60 mg of sustained-release nifedipine on myocardial perfusion. Am J Cardiol 1988;61:74-7E.
111. Rinaldi CA, Linka AZ, Masani ND, et al. Randomized, double-blind crossover study to investigate the effects of amlodipine and isosorbide mononitrate on the time course and severity of exercise-induced myocardial stunning. Circulation 1998;98:749-56.